Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Preleukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Neoplasms by Histologic Type 2Neoplasms 2Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphoma 2Lymphatic Diseases 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphoid 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Leukemia, B-Cell 2Leukemia 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Bone Marrow Diseases 2Venentoclax 1Primary Myelofibrosis 1Older Patients 1Non-Malignant Neoplasm 1Myeloproliferative Disorders 1Leukemia, Prolymphocytic 1Leukemia, Myelomonocytic, Chronic 1

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Malignant Neoplasm × fludarabine × Other neoplasm × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡